Modern ideas about the combination of bronchial asthma and chronic obstructive pulmonary disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The term «asthma-chronic obstructive pulmonary disease overlap (ACO)» is a heterogeneous condition with airflow limitation, which is not completely reversible, and also has clinical and inflammatory signs of both asthma and COPD. The study was aimed to the analysis of the material on this topic. An analytical method was used to study the diagnosis, clinical manifestations and approaches to treatment of patients with a combination of asthma and COPD over the past 10 years (2013–2023) using the following databases: PubMed, Wiley, EMBASE database, Cochrane Library.

 

Full Text

Restricted Access

About the authors

Elena Yu. Trushina

Penza Institute for Advanced Training of Physicians – Branch Campus of the RMACPE

Author for correspondence.
Email: trushina.lena@mail.ru
ORCID iD: 0000-0001-5673-9195
SPIN-code: 2164-6580

Cand. Sci. (Med.)., Associate Professor at the Department of Pulmonology and Phthisiology

Russian Federation, Penza

E. M. Kostina

Penza Institute for Advanced Training of Physicians – Branch Campus of the RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1797-8040
SPIN-code: 2111-8827
Russian Federation, Penza

V. A. Tipikin

Penza Institute for Advanced Training of Physicians – Branch Campus of the RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0009-0000-0990-4661
SPIN-code: 7403-8592
Russian Federation, Penza

E. A. Orlova

Penza Institute for Advanced Training of Physicians – Branch Campus of the RMACPE

Email: trushina.lena@mail.ru
ORCID iD: 0000-0003-1402-2940
SPIN-code: 1700-4848
Russian Federation, Penza

References

  1. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. doi: 10.1016/S0140-6736(17)32154-2.
  2. Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67:165–71. doi: 10.1016/j.alit.2018.02.002.
  3. Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) 2015. Accessed June 18, 2023. URL: https://ginasthma.org/wp-content/uploads/2016/01/ACOS_2015.pdf
  4. Fingleton J., Hardy J., Beasley R. Treatable traits of chronic airways disease. Curr Opin Pulm Med. 2018;24(1):24–31 doi: 10.1097/MCP.0000000000000445.
  5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. Accessed June 16, 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
  6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2023. Accessed June 02, 2023.
  7. Bourdin A., Suehs C.M., Marin G., et al. Asthma, COPD, and overlap in a national cohort: ACO on a gradient. J Allergy Clin Immunol. 2018;141:1516–18. doi: 10.1016/j.jaci.2017.11.049.
  8. Cataldo D., Corhay J.L., Derom E., et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–13. doi: 10.2147/COPD.S124459.
  9. Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26 doi: 10.1016/S2213-2600(18)30006-7.
  10. Tong X., Wang D., Liu S., et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–18. doi: 10.2147/COPD.S152655
  11. Liu L., Zhang X., Liu Y., et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respir Res. 2019;20:95. Doi: 10.1186 / s12931-019-1051-912. Shirai T., Hirai K., Gon Y., et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol. 2019;7:134–45. Doi: 10.1016 / j.jaip.2018.06.015
  12. Katoh S., Ikeda M., Shirai R., et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018;55:1052–58. doi: 10.1080/02770903.2017.1391281.
  13. Gon Y., Maruoka S., Ito R., et al. Utility of serum YKL-40 levels for identification of patients with asthma and COPD. Allergology International. 2017;66:624–26. Doi: 10.1016 / j.alit.2017.02.010.
  14. Jo Y.S., Kwon S.O., Kim J., et al. Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap. J Thorac Dis. 2018;10:5047–56. Doi: 10.21037 / jtd.2018.07.86.
  15. Rendell H.K., Vestibo J., Agusti A., et al. Heterogeneity within and between asthma and/or COPD diagnosed by a doctor: A NEW cohort. Int J Chron Obstruct Pulmon Dis. 2021;58:2003927. doi: 10.1183/13993003.03927-2020.
  16. Leung J.M., Sin D.D. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. Br Med J. 2017;358:j3772. Doi: 10.1136 /bmj.j3772.
  17. Hikichi M., Hashimoto S., Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67:179–86. doi: 10.1016/j.alit.2018.01.001.
  18. Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis. J Allergy Clin Immunol. 2015;136:521–29. doi: 10.1016/j.jaci.2015.06.018.
  19. Sahu A., Swaroop S., Kant S., et al. Signatures for chronic obstructive pulmonary disease (COPD) and asthma: A comparative genetic analysis. J Biomed Sci. 2021;78:177–83. doi: 10.1080/09674845.2021.1905988.
  20. Hobbs B.D., de Jong K., Lamontagne M., et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017;49:426–32. Doi: 10.1038/ ng.3752.
  21. Christenson S.A., Steiling K., van den Berge M., et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191:758–66 doi: 10.1164/rccm.201408-1458OC.
  22. Padrаo Е., Araujo D., Todo Bom A., et al. Asthma-COPD overlap: A Portuguese survey. Pulmonology. 2018;24(3):173–81. doi: 10.1016/j.rppnen.2017.11.009.
  23. Lim H.S., Choi S.M., Lee J., et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–57. Doi: 10.1016 / j.anai.2014.08.021.
  24. Lee S.Y., Park H.Y., Kim E.K., et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2797–803. doi: 10.2147/COPD.S114964.
  25. Su V.Y., Yang K.Y., Yang Y.H., et al. Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma. J Allergy Clin Immunol. 2018;6:1927–35. doi: 10.1016/j.jaip.2018.01.035.
  26. Hanania N.A., Chipps B.E., Griffin N.M., et al. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143:1629–33.e2. doi: 10.1016/j.jaci.2018.11.032.
  27. Kuprys-Lipinska I., Palczynski C., Molinska J., et al. Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. Postepy Dermatologii I Alergologii. 2019;36:239–41. doi: 10.5114/ada.2018.73140
  28. Pavord I.D., Chanez P., Criner G.J., et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377:1613–29. doi: 10.1056/NEJMoa1708208.
  29. Pavord I.D., Chapman K.R., Bafadhel M., et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–70. doi: 10.2147/COPD.S294333
  30. Criner G.J., Celli B.R., Brightling C.E., et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019;381:1023–34. doi: 10.1056/NEJMoa1905248.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies